Skip to main content
. Author manuscript; available in PMC: 2026 Oct 13.
Published in final edited form as: Lancet. 2026 May 30;407(10544):2217–2226. doi: 10.1016/S0140-6736(26)00417-4

Figure 1: Discriminative accuracy of [18F]flortaucipir and [18F]MK6240 tau PET for distinguishing clinical groups.

Figure 1:

(A) Voxelwise mean SUVRs for [18F]flortaucipir and [18F]MK6240 across different diagnostic and Aβ status groups. (B) Voxelwise AUC values for distinguishing MCI due to AD (top) or AD dementia from non-AD cognitive impairment disorders (bottom) using [18F]flortaucipir and [18F]MK6240. Participants with Alzheimer’s disease dementia were, by definition, Aβ-positive. Aβ–=amyloid-β negative. Aβ+=amyloid-β positive. AD=Alzheimer’s disease. AUC=area under the curve. CI=cognitively impaired. CU=cognitively unimpaired. MCI=mild cognitive impairment. SUVR=standardised uptake value ratio.